{{Rsnum
|rsid=652625
|Gene=TNFRSF1B
|Chromosome=1
|position=12165294
|Orientation=plus
|GMAF=0.1093
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=MIR7846,TNFRSF1B
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 87.6 | 11.5 | 0.9
| HCB | 97.1 | 2.9 | 0.0
| JPT | 99.1 | 0.9 | 0.0
| YRI | 36.7 | 53.1 | 10.2
| ASW | 52.6 | 45.6 | 1.8
| CHB | 97.1 | 2.9 | 0.0
| CHD | 97.2 | 2.8 | 0.0
| GIH | 96.0 | 4.0 | 0.0
| LWK | 32.7 | 50.0 | 17.3
| MEX | 91.4 | 6.9 | 1.7
| MKK | 56.8 | 33.5 | 9.7
| TSI | 90.2 | 9.8 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=21995493
|Title=TNFRSF1B +676 T&gt;G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoradiotherapy
|OA=1
}}

{{PMID Auto
|PMID=20300049
|Title=Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response.
}}

{{PMID Auto
|PMID=22860894
|Title=Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease
}}

{{PMID Auto
|PMID=24782596
|Title=Polymorphisms in the Tumor Necrosis Factor Receptor Genes Affect the Expression Levels of Membrane-Bound Type I and Type II Receptors
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}